{"data":{"id":"10.6084/m9.figshare.1632854","type":"dois","attributes":{"doi":"10.6084/m9.figshare.1632854","prefix":"10.6084","suffix":"m9.figshare.1632854","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Choi, Sang-Eun","nameType":"Personal","givenName":"Sang-Eun","familyName":"Choi","affiliation":[],"nameIdentifiers":[]},{"name":"Brignone, Mélanie","nameType":"Personal","givenName":"Mélanie","familyName":"Brignone","affiliation":[],"nameIdentifiers":[]},{"name":"Cho, Seong Jin","nameType":"Personal","givenName":"Seong Jin","familyName":"Cho","affiliation":[],"nameIdentifiers":[]},{"name":"Jeon, Hong Jin","nameType":"Personal","givenName":"Hong Jin","familyName":"Jeon","affiliation":[],"nameIdentifiers":[]},{"name":"Rangrhee Jung","affiliation":[],"nameIdentifiers":[]},{"name":"Campbell, Rosanne","nameType":"Personal","givenName":"Rosanne","familyName":"Campbell","affiliation":[],"nameIdentifiers":[]},{"name":"Francois, Clément","nameType":"Personal","givenName":"Clément","familyName":"Francois","affiliation":[],"nameIdentifiers":[]},{"name":"Milea, Dominique","nameType":"Personal","givenName":"Dominique","familyName":"Milea","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"Cost-effectiveness of vortioxetine \u003ci\u003eversus\u003c/i\u003e venlafaxine (extended release) in the treatment of major depressive disorder in South Korea"}],"publisher":"Taylor \u0026 Francis","container":{},"publicationYear":2016,"subjects":[{"subject":"Medicine"},{"subject":"Biotechnology"},{"subject":"111714 Mental Health","subjectScheme":"FOR"},{"subject":"FOS: Health sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Health sciences","subjectScheme":"Fields of Science and Technology (FOS)"}],"contributors":[],"dates":[{"date":"2016-01-13","dateType":"Created"},{"date":"2016-12-05","dateType":"Updated"},{"date":"2016","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[{"relationType":"IsSupplementTo","relatedIdentifier":"10.1586/14737167.2016.1128830","relatedIdentifierType":"DOI"}],"relatedItems":[],"sizes":["341784 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"\u003cb\u003eObjective\u003c/b\u003e: To assess the cost-effectiveness of vortioxetine \u003ci\u003eversus\u003c/i\u003e venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. \u003cb\u003eMethods\u003c/b\u003e: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states. \u003cb\u003eResults\u003c/b\u003e: Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1 year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations. \u003cb\u003eConclusion\u003c/b\u003e: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"PD94bWwgdmVyc2lvbj0iMS4wIiBlbmNvZGluZz0iVVRGLTgiPz4KPHJlc291cmNlIHhtbG5zPSJodHRwOi8vZGF0YWNpdGUub3JnL3NjaGVtYS9rZXJuZWwtNCIgeG1sbnM6eHNpPSJodHRwOi8vd3d3LnczLm9yZy8yMDAxL1hNTFNjaGVtYS1pbnN0YW5jZSIgeHNpOnNjaGVtYUxvY2F0aW9uPSJodHRwOi8vZGF0YWNpdGUub3JnL3NjaGVtYS9rZXJuZWwtNCBodHRwOi8vc2NoZW1hLmRhdGFjaXRlLm9yZy9tZXRhL2tlcm5lbC00LjEvbWV0YWRhdGEueHNkIj4KICA8aWRlbnRpZmllciBpZGVudGlmaWVyVHlwZT0iRE9JIj4xMC42MDg0L005LkZJR1NIQVJFLjE2MzI4NTQ8L2lkZW50aWZpZXI+CiAgPGNyZWF0b3JzPgogICAgPGNyZWF0b3I+CiAgICAgIDxjcmVhdG9yTmFtZT5TYW5nLUV1biBDaG9pPC9jcmVhdG9yTmFtZT4KICAgIDwvY3JlYXRvcj4KICAgIDxjcmVhdG9yPgogICAgICA8Y3JlYXRvck5hbWU+TcOpbGFuaWUgQnJpZ25vbmU8L2NyZWF0b3JOYW1lPgogICAgPC9jcmVhdG9yPgogICAgPGNyZWF0b3I+CiAgICAgIDxjcmVhdG9yTmFtZT5TZW9uZyBKaW4gQ2hvPC9jcmVhdG9yTmFtZT4KICAgIDwvY3JlYXRvcj4KICAgIDxjcmVhdG9yPgogICAgICA8Y3JlYXRvck5hbWU+SG9uZyBKaW4gSmVvbjwvY3JlYXRvck5hbWU+CiAgICA8L2NyZWF0b3I+CiAgICA8Y3JlYXRvcj4KICAgICAgPGNyZWF0b3JOYW1lPlJhbmdyaGVlIEp1bmc8L2NyZWF0b3JOYW1lPgogICAgPC9jcmVhdG9yPgogICAgPGNyZWF0b3I+CiAgICAgIDxjcmVhdG9yTmFtZT5Sb3Nhbm5lIENhbXBiZWxsPC9jcmVhdG9yTmFtZT4KICAgIDwvY3JlYXRvcj4KICAgIDxjcmVhdG9yPgogICAgICA8Y3JlYXRvck5hbWU+Q2zDqW1lbnQgRnJhbmNvaXM8L2NyZWF0b3JOYW1lPgogICAgPC9jcmVhdG9yPgogICAgPGNyZWF0b3I+CiAgICAgIDxjcmVhdG9yTmFtZT5Eb21pbmlxdWUgTWlsZWE8L2NyZWF0b3JOYW1lPgogICAgPC9jcmVhdG9yPgogIDwvY3JlYXRvcnM+CiAgPHRpdGxlcz4KICAgIDx0aXRsZT5Db3N0LWVmZmVjdGl2ZW5lc3Mgb2Ygdm9ydGlveGV0aW5lICZsdDtpJmd0O3ZlcnN1cyZsdDsvaSZndDsgdmVubGFmYXhpbmUgKGV4dGVuZGVkIHJlbGVhc2UpIGluIHRoZSB0cmVhdG1lbnQgb2YgbWFqb3IgZGVwcmVzc2l2ZSBkaXNvcmRlciBpbiBTb3V0aCBLb3JlYTwvdGl0bGU+CiAgPC90aXRsZXM+CiAgPGRlc2NyaXB0aW9ucz4KICAgIDxkZXNjcmlwdGlvbiBkZXNjcmlwdGlvblR5cGU9IkFic3RyYWN0Ij4mbHQ7cCZndDsmbHQ7YiZndDtPYmplY3RpdmUmbHQ7L2ImZ3Q7OiBUbyBhc3Nlc3MgdGhlIGNvc3QtZWZmZWN0aXZlbmVzcyBvZiB2b3J0aW94ZXRpbmUgJmx0O2kmZ3Q7dmVyc3VzJmx0Oy9pJmd0OyB2ZW5sYWZheGluZSBYUiAoZXh0ZW5kZWQtcmVsZWFzZSkgaW4gbWFqb3IgZGVwcmVzc2l2ZSBkaXNvcmRlciAoTUREKSBwYXRpZW50cyBpbiBTb3V0aCBLb3JlYS4mbHQ7L3AmZ3Q7ICZsdDtwJmd0OyZsdDtiJmd0O01ldGhvZHMmbHQ7L2ImZ3Q7OiBBIDEteWVhciBjb3N0LWVmZmVjdGl2ZW5lc3MgYW5hbHlzaXMgZnJvbSBhIGxpbWl0ZWQgc29jaWV0YWwgcGVyc3BlY3RpdmUgd2FzIHBlcmZvcm1lZCB1c2luZyBhIGNvbWJpbmVkIG1vZGVsIGNvbnNpc3Rpbmcgb2YgYSBkZWNpc2lvbi10cmVlIGFuZCBhIE1hcmtvdiBtb2RlbC4gUGF0aWVudHMgZW50ZXJlZCB0aGUgbW9kZWwgd2hlbiBpbml0aWF0aW5nIG9yIHN3aXRjaGluZyBhbnRpZGVwcmVzc2FudCB0cmVhdG1lbnQgZm9sbG93aW5nIGluYWRlcXVhdGUgcmVzcG9uc2UgdG8gcHJldmlvdXMgdHJlYXRtZW50LiBSZW1pc3Npb24sIHJlbGFwc2UgYW5kIHJlY292ZXJ5IHdlcmUgdGhlIG1haW4gaGVhbHRoIHN0YXRlcy4mbHQ7L3AmZ3Q7ICZsdDtwJmd0OyZsdDtiJmd0O1Jlc3VsdHMmbHQ7L2ImZ3Q7OiBWb3J0aW94ZXRpbmUgZG9taW5hdGVkIHZlbmxhZmF4aW5lIFhSLCB3aXRoIHF1YWxpdHktYWRqdXN0ZWQgbGlmZSB5ZWFyIChRQUxZKSBnYWlucyBvZiAwLjAxMzEgYW5kIGNvc3Qgc2F2aW5ncyBvZiBLUlcgNjIzLDIyOS95ZWFyIFtVUyQ1MzAveWVhcl0gZnJvbSBhIGxpbWl0ZWQgc29jaWV0YWwgcGVyc3BlY3RpdmUuIFNhZmV0eSBjb250cmlidXRlZCBtb3JlIHRoYW4gZWZmaWNhY3kgdG8gdGhlIGluY3JlbWVudGFsIFFBTFkgZ2FpbnMuIE1vcmUgcGF0aWVudHMgd2VyZSBpbiByZWNvdmVyeSBhZnRlciBpbml0aWFsIHRyZWF0bWVudCBhbmQgYWZ0ZXIgMcKgeWVhciB3aXRoIHZvcnRpb3hldGluZSAoMzElLCA0MCUpIGNvbXBhcmVkIHRvIHZlbmxhZmF4aW5lIFhSICgyMyUsIDM2JSkuIFZvcnRpb3hldGluZSByZW1haW5lZCBkb21pbmFudCBpbiA5OCUgb2YgcHJvYmFiaWxpc3RpYyBzaW11bGF0aW9ucy4mbHQ7L3AmZ3Q7ICZsdDtwJmd0OyZsdDtiJmd0O0NvbmNsdXNpb24mbHQ7L2ImZ3Q7OiBWb3J0aW94ZXRpbmUgZG9taW5hdGVkIHZlbmxhZmF4aW5lIFhSIGluIFNvdXRoIEtvcmVhIGFuZCBpcyBhIHJlbGV2YW50IHRyZWF0bWVudCBvcHRpb24gZm9yIE1ERCBwYXRpZW50cyBpbml0aWF0aW5nIG9yIHN3aXRjaGluZyB0aGVyYXB5LiZsdDsvcCZndDs8L2Rlc2NyaXB0aW9uPgogIDwvZGVzY3JpcHRpb25zPgogIDxzdWJqZWN0cz4KICAgIDxzdWJqZWN0Pk1lZGljaW5lPC9zdWJqZWN0PgogICAgPHN1YmplY3Q+QmlvdGVjaG5vbG9neTwvc3ViamVjdD4KICAgIDxzdWJqZWN0IHNjaGVtZVVSST0iaHR0cDovL3d3dy5hYnMuZ292LmF1L2F1c3N0YXRzL2Fic0AubnNmLzAvNkJCNDI3QUI5Njk2QzIyNUNBMjU3NDE4MDAwNDQ2M0UiIHN1YmplY3RTY2hlbWU9IkZPUiI+MTExNzE0IE1lbnRhbCBIZWFsdGg8L3N1YmplY3Q+CiAgPC9zdWJqZWN0cz4KICA8cHVibGlzaGVyPlRheWxvciAmYW1wOyBGcmFuY2lzPC9wdWJsaXNoZXI+CiAgPHB1YmxpY2F0aW9uWWVhcj4yMDE2PC9wdWJsaWNhdGlvblllYXI+CiAgPGRhdGVzPgogICAgPGRhdGUgZGF0ZVR5cGU9IkNyZWF0ZWQiPjIwMTYtMDEtMTM8L2RhdGU+CiAgICA8ZGF0ZSBkYXRlVHlwZT0iVXBkYXRlZCI+MjAxNi0xMi0wNTwvZGF0ZT4KICA8L2RhdGVzPgogIDxyZXNvdXJjZVR5cGUgcmVzb3VyY2VUeXBlR2VuZXJhbD0iRGF0YXNldCI+RGF0YXNldDwvcmVzb3VyY2VUeXBlPgogIDxzaXplcz4KICAgIDxzaXplPjM0MTc4NCBCeXRlczwvc2l6ZT4KICA8L3NpemVzPgogIDxyZWxhdGVkSWRlbnRpZmllcnM+CiAgICA8cmVsYXRlZElkZW50aWZpZXIgcmVsYXRlZElkZW50aWZpZXJUeXBlPSJET0kiIHJlbGF0aW9uVHlwZT0iSXNTdXBwbGVtZW50VG8iPjEwLjE1ODYvMTQ3MzcxNjcuMjAxNi4xMTI4ODMwPC9yZWxhdGVkSWRlbnRpZmllcj4KICA8L3JlbGF0ZWRJZGVudGlmaWVycz4KICA8cmlnaHRzTGlzdD4KICAgIDxyaWdodHMgcmlnaHRzVVJJPSJodHRwczovL2NyZWF0aXZlY29tbW9ucy5vcmcvbGljZW5zZXMvYnkvNC4wLyI+Q0MgQlkgNC4wPC9yaWdodHM+CiAgPC9yaWdodHNMaXN0Pgo8L3Jlc291cmNlPg==","url":"https://tandf.figshare.com/articles/dataset/Cost_effectiveness_of_vortioxetine_i_versus_i_venlafaxine_extended_release_in_the_treatment_of_major_depressive_disorder_in_South_Korea/1632854","contentUrl":null,"metadataVersion":2,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2016-01-13T16:34:00.000Z","registered":"2016-01-13T16:34:01.000Z","published":"2016","updated":"2020-09-04T13:50:13.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.1632854","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}